Scholar's Digest : Journal of Neurology
Vol. 1, No. 1, Year 2025
Website : https://scholarsdigest.org.in/index.php/sdjn
PUBLISHED: 2025-04-16

The Role of Neuroinflammation in Neurodegenerative Diseases: Mechanisms and Therapeutic Implications

Savita, Assistant Professor, GGJ Govt. College, Hisar, Haryana

Abstract

Neuroinflammation has emerged as a critical pathological feature in various neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). This paper aims to explore the mechanisms underlying neuroinflammation and its role in the progression of neurodegenerative diseases. It also discusses potential therapeutic implications for targeting neuroinflammatory processes, with a focus on anti-inflammatory agents, immune modulation, and novel approaches that hold promise for treating these debilitating conditions. Through a comprehensive review of the current literature, this paper presents insights into the complex relationship between neuroinflammation and neurodegeneration, underscoring the need for continued research into effective therapeutic strategies.

Keywords: neuroinflammation, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, therapeutic implications, anti-inflammatory therapies, immune modulation.

1. Introduction

Neurodegenerative diseases (NDs) such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) are among the leading causes of disability and death worldwide. These diseases are characterized by the progressive degeneration of neurons, resulting in cognitive decline, motor dysfunction, and in some cases, death. While the primary etiological factors in NDs remain incompletely understood, growing evidence highlights the role of neuroinflammation as a significant contributor to disease pathogenesis. Neuroinflammation refers to the activation of the brain's innate immune system, involving microglia and astrocytes, in response to neuronal injury or dysfunction (Heneka et al., 2015). This paper examines the role of neuroinflammation in NDs, the mechanisms through which it

contributes to disease progression, and the therapeutic implications of targeting neuroinflammatory pathways.

2. Neuroinflammation and Its Mechanisms

Neuroinflammation is a multifaceted process that can have both protective and deleterious effects. Under normal circumstances, microglia, the resident immune cells of the central nervous system (CNS), respond to injury or infection by releasing pro-inflammatory cytokines and recruiting additional immune cells (Liu & Hong, 2018). However, in neurodegenerative diseases, this immune response becomes dysregulated, contributing to chronic inflammation and neuronal damage. Neuroinflammation is a key process in the central nervous system (CNS) that involves the activation of the brain's immune cells, primarily microglia and astrocytes, in response to various forms of injury, infection, or disease. While acute neuroinflammation can be a protective response that helps to repair damage and fight infections, chronic neuroinflammation is often linked to the progression of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). In these conditions, neuroinflammation becomes dysregulated and leads to sustained damage to neurons and other CNS cells, exacerbating disease progression.

2.1. Microglial Activation

Microglia are the resident immune cells of the brain and are essential for maintaining homeostasis within the CNS. In a healthy brain, microglia perform important tasks such as synaptic pruning, promoting neuronal survival, and maintaining the blood-brain barrier. However, when the brain encounters stressors such as pathogens, injury, or the accumulation of toxic proteins, microglia become activated.

- **Activation Mechanism**: Upon activation, microglia undergo morphological changes and become motile. They release pro-inflammatory cytokines (e.g., TNF-α, IL-1β), chemokines, and reactive oxygen species (ROS), which act to recruit other immune cells, amplify inflammation, and clear damaged cells. In neurodegenerative diseases, microglia may also become "primed," meaning they respond more aggressively to subsequent stimuli, contributing to chronic inflammation.

- **Negative Effects**: Although initially beneficial, prolonged activation of microglia in neurodegenerative diseases leads to a vicious cycle of chronic inflammation. Overproduction of ROS and pro-inflammatory cytokines can result in neuronal damage, synaptic dysfunction, and even neuronal death. Microglial activation is particularly implicated in diseases like Alzheimer's, where amyloid-beta plaques activate microglia, leading to neurodegeneration (Heneka et al., 2015).

2.2. Astrocyte Dysfunction

Astrocytes are another type of glial cell in the CNS that play crucial roles in supporting neuronal function, maintaining the blood-brain barrier, and regulating neurotransmitter balance. In response to injury or disease, astrocytes can become reactive.

- **Astrocyte Activation**: Reactivity in astrocytes manifests as a change in shape, upregulation of pro-inflammatory cytokines, and increased production of glial fibrillary acidic protein (GFAP), a marker of astrogliosis. While reactive astrocytes can help repair damaged tissue and protect neurons, excessive or sustained activation can contribute to neuroinflammation and exacerbate neuronal damage.

- **Contributions to Neuroinflammation**: In neurodegenerative diseases, reactive astrocytes release pro-inflammatory cytokines, chemokines, and ROS, which increase the inflammatory burden in the CNS. This amplification of the inflammatory response can interfere with neuronal function and survival (Zhao et al., 2017). For example, in Alzheimer's disease, astrocytes surrounding amyloid plaques become activated and exacerbate the inflammatory environment.

2.3. Blood-Brain Barrier Disruption

The blood-brain barrier (BBB) is a selectively permeable membrane that regulates the exchange of molecules between the blood and the brain. Under normal circumstances, the BBB protects the brain from harmful substances and prevents the infiltration of peripheral immune cells. However, chronic neuroinflammation can disrupt the integrity of the BBB.

- **Mechanism of BBB Breakdown**: In the presence of sustained neuroinflammation, pro-inflammatory cytokines can affect the tight junctions between endothelial cells that form the BBB. This disruption leads to an increase in the permeability of the BBB, allowing

peripheral immune cells, such as macrophages, and inflammatory mediators to enter the CNS, further promoting inflammation and neurodegeneration.

- **Implications for Disease**: The disruption of the BBB is particularly prominent in Alzheimer's disease and other neurodegenerative conditions. The infiltration of peripheral immune cells exacerbates the local inflammatory response, which in turn accelerates neuronal damage and disease progression (Perry et al., 2018).

2.4. Inflammasome Activation

The inflammasome is a multiprotein complex that plays a key role in the innate immune response by activating caspase-1, which in turn leads to the maturation and secretion of pro-inflammatory cytokines, such as IL-1β and IL-18. Inflammasome activation is increasingly recognized as a central mechanism in neuroinflammation.

- **Mechanism of Inflammasome Activation**: In neurodegenerative diseases, the inflammasome can be activated by the accumulation of misfolded proteins (e.g., amyloid-beta in Alzheimer's disease, alpha-synuclein in Parkinson's disease) or other danger signals from dying cells. The NLRP3 inflammasome, in particular, has been implicated in Alzheimer's disease, where it is activated by amyloid plaques and contributes to the release of IL-1β and IL-18 (Guo et al., 2016).

- **Role in Neurodegeneration**: The activation of the inflammasome leads to a cascade of inflammatory events that contribute to neurodegeneration. In Alzheimer's disease, the release of IL-1β and other inflammatory cytokines promotes neuronal damage, synaptic loss, and cognitive decline (Heneka et al., 2015).

2.5. Reactive Oxygen Species (ROS) Production

Reactive oxygen species (ROS) are highly reactive molecules that are generated as byproducts of cellular metabolism. Under normal conditions, ROS are involved in signaling and immune responses. However, when produced in excess during neuroinflammation, ROS can cause cellular damage and contribute to neurodegeneration.

- **Mechanism of ROS Production**: Both microglia and astrocytes produce ROS during the inflammatory response. Excessive ROS production can lead to oxidative stress, which damages lipids, proteins, and DNA, contributing to neuronal dysfunction and death. In

diseases like Parkinson's disease, ROS are thought to play a key role in the degeneration of dopaminergic neurons (Arezzo et al., 2018).

- **Consequences of ROS in Neurodegeneration**: The accumulation of ROS in the brain can damage cellular structures and disrupt neuronal signaling, thereby accelerating disease progression. In Alzheimer's disease, for example, oxidative stress is implicated in amyloid-beta toxicity, mitochondrial dysfunction, and tau hyperphosphorylation, all of which contribute to the neurodegenerative process.

Neuroinflammation is a complex, multifactorial process that plays a central role in the development and progression of many neurodegenerative diseases. The activation of microglia and astrocytes, the disruption of the blood-brain barrier, inflammasome activation, and ROS production are some of the key mechanisms by which neuroinflammation contributes to neuronal damage and disease progression. While neuroinflammation serves a protective role in the early stages of injury, its chronic activation in neurodegenerative diseases leads to a vicious cycle of inflammation and neurodegeneration. Understanding the detailed mechanisms of neuroinflammation is essential for developing targeted therapeutic strategies aimed at modulating this process in order to slow or halt disease progression in conditions such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.

3. Neuroinflammation in Alzheimer's Disease

Alzheimer's disease (AD), the most common neurodegenerative disorder, is characterized by the accumulation of amyloid-beta plaques and tau tangles in the brain. Neuroinflammation plays a central role in AD pathogenesis, with evidence suggesting that the activation of microglia in response to amyloid plaques accelerates neurodegeneration. Activated microglia release pro-inflammatory cytokines, such as TNF-α and IL-1β, which contribute to synaptic loss and neuronal death (Heneka et al., 2015). Additionally, astrocytes in AD brains show increased reactivity, contributing to the exacerbation of inflammation and further neuronal damage (Zhao et al., 2017).

Recent studies suggest that modulating neuroinflammation may offer therapeutic benefits for AD. For instance, inhibitors of the NLRP3 inflammasome have been shown to reduce neuroinflammation and improve cognitive function in animal models of AD (Guo et al.,

2016). Furthermore, anti-inflammatory drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs), have been explored as potential treatments for AD, though clinical trials have yielded mixed results (Aisen et al., 2017). Alzheimer's disease (AD) is the most common form of dementia and is characterized by progressive cognitive decline, memory loss, and behavioral changes. While the accumulation of amyloid-beta plaques and tau tangles are the hallmark pathological features of AD, neuroinflammation has increasingly been recognized as a critical process that contributes to disease progression. Neuroinflammation in AD involves the activation of the brain's immune cells, primarily microglia and astrocytes, and the release of pro-inflammatory mediators. This chronic inflammation exacerbates neuronal damage and plays a significant role in the cognitive decline seen in AD.

3.1 Mechanisms of Neuroinflammation in Alzheimer's Disease

- **Microglial Activation**
    - **Role of Microglia**: Microglia are the resident immune cells of the central nervous system (CNS) and act as the brain's first line of defense against injury and disease. Under normal conditions, microglia perform important functions, such as removing damaged neurons, supporting synaptic plasticity, and maintaining overall brain homeostasis. However, in Alzheimer's disease, microglia become chronically activated in response to amyloid-beta plaques.
    - **Activation Mechanism**: Amyloid-beta, a protein that aggregates to form plaques in the brains of AD patients, activates microglia through pattern recognition receptors (PRRs), such as the toll-like receptor 4 (TLR4). Upon activation, microglia release pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), as well as reactive oxygen species (ROS). While microglial activation is initially protective, chronic activation leads to sustained inflammation, which worsens neuronal damage and promotes disease progression (Heneka et al., 2015).
    - **Microglial Priming**: In AD, microglia become "primed" or hypersensitive, meaning they respond more vigorously to subsequent stimuli, perpetuating a cycle of inflammation. This priming effect can result in increased production of pro-inflammatory molecules that drive neurodegeneration. Additionally, primed

microglia are less effective at clearing amyloid plaques, further contributing to plaque accumulation (Sastre et al., 2006).

- **Astrocyte Dysfunction**
    - **Role of Astrocytes**: Astrocytes, another type of glial cell in the brain, are crucial for maintaining the blood-brain barrier, regulating neurotransmitter levels, and supporting neuronal function. In response to injury or disease, astrocytes become reactive and play a role in neuroinflammation.
    - **Astrocyte Activation in AD**: In Alzheimer's disease, astrocytes around amyloid plaques become activated and exhibit an inflammatory phenotype. Reactive astrocytes upregulate the expression of pro-inflammatory cytokines, chemokines, and other signaling molecules, including GFAP (glial fibrillary acidic protein), a marker of astrogliosis. This increased reactivity exacerbates inflammation and damages neurons and synapses (Zhao et al., 2017).
    - **Cross-talk with Microglia**: Astrocytes and microglia engage in bidirectional communication in the context of AD. Astrocytes can release signals that activate microglia, and vice versa. This cross-talk amplifies the inflammatory response, contributing to the chronic neuroinflammation that is a hallmark of AD (Heneka et al., 2015).
- **Inflammasome Activation**
    - **Inflammasome and Neuroinflammation**: The inflammasome is a multi-protein complex that plays a key role in innate immune responses by activating caspase-1, which leads to the maturation of pro-inflammatory cytokines such as IL-1β and IL-18. In Alzheimer's disease, the NLRP3 inflammasome is activated in response to the accumulation of amyloid-beta plaques. Once activated, the inflammasome triggers a cascade of pro-inflammatory cytokine release, which exacerbates neuroinflammation and contributes to neuronal dysfunction (Guo et al., 2016).
    - **Impact on Disease Progression**: The activation of the inflammasome in AD results in increased levels of IL-1β and other inflammatory cytokines that further promote the degeneration of neurons and synapses. This amplification of

inflammation accelerates cognitive decline and worsens the overall prognosis of AD patients (Heneka et al., 2015).

- **Blood-Brain Barrier Disruption**
    - **Compromise of the BBB**: The blood-brain barrier (BBB) is a selective barrier that protects the brain from harmful substances and regulates the exchange of nutrients and waste products. In Alzheimer's disease, chronic neuroinflammation can lead to a breakdown of the BBB. Pro-inflammatory cytokines, including TNF-α and IL-1β, can disrupt the tight junctions between endothelial cells that form the BBB, making it more permeable.
    - **Consequences of BBB Disruption**: Once the BBB is compromised, peripheral immune cells, such as T cells and monocytes, can infiltrate the brain and exacerbate neuroinflammation. Additionally, harmful substances, such as circulating cytokines and toxins, can enter the brain, further exacerbating neuronal injury. The infiltration of peripheral immune cells into the CNS may also perpetuate the inflammatory environment, worsening disease progression (Perry et al., 2018).
- **Reactive Oxygen Species (ROS) and Oxidative Stress**
    - **Role of ROS**: Reactive oxygen species (ROS) are chemically reactive molecules that can cause oxidative damage to cellular components, including lipids, proteins, and DNA. Under normal circumstances, ROS are involved in immune signaling and other cellular processes. However, in Alzheimer's disease, activated microglia and astrocytes produce excessive ROS as part of the inflammatory response.
    - **Impact on Neurons**: Excessive ROS production in AD contributes to oxidative stress, which leads to the damage of neuronal structures and dysfunction of cellular processes. ROS-induced damage can accelerate amyloid-beta aggregation, impair mitochondrial function, and lead to the activation of cell death pathways. This oxidative damage is one of the key contributors to neuronal loss and cognitive decline in AD (Zhao et al., 2017).

3.2 Impact of Neuroinflammation on Disease Progression

Neuroinflammation plays a significant role in the progression of Alzheimer's disease. The chronic activation of microglia and astrocytes, the release of pro-inflammatory cytokines, and the accumulation of ROS all contribute to a toxic environment that exacerbates neuronal damage. This inflammation promotes the formation of amyloid plaques and tau tangles, which are the hallmark pathologies of AD, and accelerates synaptic dysfunction and neuronal death.

- **Cognitive Decline**: Chronic neuroinflammation in AD is closely linked to cognitive decline. Pro-inflammatory cytokines, such as TNF-α and IL-1β, interfere with synaptic plasticity and neuronal signaling, impairing learning and memory. In animal models, inhibition of microglial activation has been shown to reduce cognitive deficits, suggesting that controlling neuroinflammation may have therapeutic potential (Heneka et al., 2015).
- **Synaptic Dysfunction**: Synapses are the sites of communication between neurons, and their dysfunction is an early event in Alzheimer's disease. Neuroinflammation impairs synaptic function by altering the release of neurotransmitters, disrupting the formation of new synapses, and promoting synaptic loss. The chronic inflammatory response can also interfere with the ability of neurons to maintain proper communication with one another, contributing to the progressive cognitive decline seen in AD (Zhao et al., 2017).
- **Amyloid-Beta and Tau Pathology**: Neuroinflammation plays a role in promoting the aggregation of amyloid-beta and tau, two key proteins involved in AD pathogenesis. Microglial activation in response to amyloid plaques leads to the release of pro-inflammatory cytokines and ROS, which can exacerbate amyloid-beta deposition and tau phosphorylation. Additionally, the inflammasome, particularly the NLRP3 complex, has been implicated in the processing and clearance of amyloid-beta, further linking inflammation to amyloid pathology (Guo et al., 2016).

3.3 Therapeutic Implications

Given the central role of neuroinflammation in Alzheimer's disease, targeting the inflammatory pathways that contribute to disease progression offers a promising avenue for therapeutic intervention. Potential strategies include:

- **Anti-inflammatory Drugs**: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been explored for their ability to reduce neuroinflammation, although clinical trials have shown mixed results. More targeted approaches, such as the use of IL-1β inhibitors or NLRP3 inflammasome inhibitors, may prove more effective (Aisen et al., 2017).

- **Microglial and Astrocyte Modulation**: Drugs that modulate microglial activation or astrocyte function could help reduce neuroinflammation. For example, compounds that inhibit TLR4 signaling or that promote the "alternatively activated" phenotype of microglia, which has anti-inflammatory properties, are being investigated as potential therapies (Heneka et al., 2015).

- **Lifestyle Interventions**: Research suggests that lifestyle factors, such as exercise, diet, and stress management, can modulate neuroinflammation. For instance, anti-inflammatory diets (e.g., Mediterranean diet) have been associated with a reduced risk of developing Alzheimer's disease (Keshavarzian et al., 2015).

Neuroinflammation plays a crucial role in the pathogenesis and progression of Alzheimer's disease. The activation of microglia and astrocytes, the release of pro-inflammatory cytokines, and the production of ROS contribute to neuronal damage, cognitive decline, and the accumulation of amyloid-beta plaques and tau tangles. Understanding the mechanisms of neuroinflammation in AD offers the potential for developing novel therapeutic strategies aimed at modulating the brain's immune response to slow or halt disease progression. Continued research into this area is essential for identifying effective treatments for Alzheimer's disease.

4. Neuroinflammation in Parkinson's Disease

Parkinson's disease (PD) is another major neurodegenerative disorder, characterized by the loss of dopaminergic neurons in the substantia nigra. Neuroinflammation plays a critical role in the progression of PD, as evidenced by the activation of microglia in the affected brain regions. In PD, alpha-synuclein aggregates into Lewy bodies, which can trigger an inflammatory response from microglia and astrocytes. The chronic release of inflammatory cytokines and ROS accelerates dopaminergic neuron death, leading to motor symptoms (Arezzo et al., 2018).

Recent advances in PD therapy have focused on modulating neuroinflammation. For example, certain immunomodulatory therapies, such as TLR4 antagonists, have shown promise in reducing inflammation and protecting dopaminergic neurons in preclinical models (Ravina et al., 2020). Additionally, targeting the gut-brain axis, which influences neuroinflammation, is emerging as a potential therapeutic strategy for PD (Keshavarzian et al., 2015). Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra, a region of the brain involved in motor control. The clinical symptoms of PD, including tremors, bradykinesia (slowness of movement), rigidity, and postural instability, arise from the depletion of dopamine, a neurotransmitter that is critical for regulating movement. Although the primary pathological feature of PD is the degeneration of dopaminergic neurons, increasing evidence suggests that neuroinflammation plays a significant role in disease progression. In PD, neuroinflammation is largely driven by the activation of microglia and astrocytes, the brain's immune cells, in response to both genetic and environmental factors.

4.1 Mechanisms of Neuroinflammation in Parkinson's Disease

- **Microglial Activation**

  - **Role of Microglia in Parkinson's Disease**: Microglia are the resident immune cells of the central nervous system (CNS). Under normal conditions, they perform several important functions, such as clearing debris and supporting neuronal health. However, in Parkinson's disease, microglia become activated and adopt a pro-inflammatory phenotype, contributing to neuroinflammation. This activation is thought to be triggered by factors such as the accumulation of misfolded proteins, oxidative stress, and environmental toxins.

  - **Activation Mechanism**: Microglia in PD are primarily activated in response to the accumulation of α-synuclein, a protein that aggregates to form Lewy bodies, which are pathological hallmarks of PD. Misfolded α-synuclein can activate microglial receptors, such as toll-like receptors (TLRs) and NOD-like receptors (NLRs), leading to the release of pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6, as well as reactive oxygen species (ROS) (McGeer et al., 2003). Chronic microglial activation leads to the release of

inflammatory mediators that further damage dopaminergic neurons, accelerating the progression of the disease.

- **Neurotoxic Effects**: Although microglia initially respond to injury in a protective manner, persistent activation of microglia in PD contributes to neurodegeneration. The prolonged release of pro-inflammatory cytokines and ROS by activated microglia can lead to oxidative stress, mitochondrial dysfunction, and neuronal death. Additionally, microglial activation can disrupt the blood-brain barrier (BBB), allowing peripheral immune cells to enter the brain and exacerbate inflammation (Hunot et al., 1999).

- **Astrocyte Dysfunction**

- **Role of Astrocytes**: Astrocytes are a type of glial cell that support neuronal function, maintain the integrity of the blood-brain barrier, regulate neurotransmitter levels, and provide metabolic support to neurons. In PD, astrocytes become reactive in response to neuronal injury and neuroinflammation.

- **Astrocyte Activation in PD**: Reactive astrocytes exhibit morphological changes, upregulate the expression of glial fibrillary acidic protein (GFAP), and release pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. Astrocytes can also release glutamate, an excitatory neurotransmitter, in excessive amounts, contributing to excitotoxicity and further neuronal damage (Guillemin et al., 2005). Astrocytic activation in PD can also impair dopaminergic function by disrupting the extracellular environment and promoting neuronal degeneration.

- **Cross-talk Between Microglia and Astrocytes**: In Parkinson's disease, microglia and astrocytes communicate in a bidirectional manner. Activated microglia can release signals that stimulate astrocytes, and reactive astrocytes can in turn activate microglia, amplifying the inflammatory response. This positive feedback loop contributes to the chronic inflammation and neuronal damage observed in PD (Liddelow et al., 2017).

- **Inflammasome Activation**

- **The Role of the Inflammasome**: The inflammasome is a protein complex that regulates the activation of caspase-1, an enzyme that processes pro-inflammatory cytokines such as IL-1β and IL-18 into their active forms. In Parkinson's disease, the NLRP3

inflammasome has been implicated in driving neuroinflammation. NLRP3 is activated by a variety of stimuli, including α-synuclein aggregates and oxidative stress.

- **Activation of the NLRP3 Inflammasome in PD**: In the context of PD, the accumulation of misfolded α-synuclein and other damage-associated molecular patterns (DAMPs) triggers the activation of the NLRP3 inflammasome in both microglia and astrocytes. This leads to the release of pro-inflammatory cytokines, particularly IL-1β, which plays a key role in amplifying the inflammatory response and contributing to neuronal injury (Gardai et al., 2007). Inflammasome activation is particularly relevant in PD because it not only promotes inflammation but also disrupts the homeostasis of dopaminergic neurons.

- **Inflammasome Inhibition as a Therapeutic Target**: Targeting the NLRP3 inflammasome has been proposed as a potential therapeutic strategy in Parkinson's disease. Preclinical studies have shown that inhibiting NLRP3 can reduce neuroinflammation and protect dopaminergic neurons in animal models of PD (Liu et al., 2016).

- **Oxidative Stress and Mitochondrial Dysfunction**

- **Oxidative Stress in PD**: Oxidative stress plays a central role in the pathogenesis of Parkinson's disease. The activation of microglia and astrocytes leads to the production of reactive oxygen species (ROS), which can damage cellular structures, including lipids, proteins, and DNA. In PD, the accumulation of ROS accelerates the degeneration of dopaminergic neurons by impairing mitochondrial function, disrupting cellular signaling, and promoting cell death (Schapira et al., 2014).

- **Mitochondrial Dysfunction**: In PD, dopaminergic neurons are particularly vulnerable to mitochondrial dysfunction due to their high metabolic demand and reliance on mitochondrial energy production. Mitochondrial impairment leads to a reduction in ATP production and an increase in ROS, further exacerbating neuroinflammation. This cycle of oxidative stress and mitochondrial dysfunction accelerates the death of dopaminergic neurons in the substantia nigra (Greenamyre et al., 2011).

- **Blood-Brain Barrier Disruption**

- **BBB Breakdown in PD**: The blood-brain barrier (BBB) is a selectively permeable membrane that protects the brain from harmful substances and regulates the exchange of nutrients. In Parkinson's disease, chronic neuroinflammation can lead to a breakdown of the BBB, making the brain more susceptible to immune cell infiltration and the entry of potentially harmful substances.

- **Peripheral Immune Cell Infiltration**: The disruption of the BBB allows peripheral immune cells, such as monocytes and T cells, to enter the brain and contribute to the inflammatory response. This infiltration of immune cells exacerbates neuroinflammation and accelerates the progression of neurodegeneration in PD (Kaur et al., 2018). The resulting inflammatory environment further impairs neuronal function and survival.

4.2 Impact of Neuroinflammation on Disease Progression

Neuroinflammation in Parkinson's disease is a critical factor in disease progression. The activation of microglia and astrocytes, the release of pro-inflammatory cytokines, oxidative stress, and mitochondrial dysfunction all contribute to the ongoing degeneration of dopaminergic neurons in the substantia nigra. This inflammation is thought to worsen motor symptoms and accelerate cognitive decline in PD patients.

- **Motor Symptoms**: Chronic neuroinflammation in PD contributes to the progressive motor symptoms by exacerbating dopaminergic neuronal death. The sustained release of pro-inflammatory mediators by activated microglia and astrocytes leads to a toxic environment that accelerates the degeneration of dopaminergic neurons in the striatum, resulting in worsening motor dysfunction.

- **Cognitive Decline**: In addition to motor symptoms, neuroinflammation in PD is also associated with cognitive decline. Inflammation can impair synaptic plasticity and disrupt normal neural circuits involved in cognition. Studies suggest that neuroinflammation in the hippocampus and other brain regions can contribute to the development of dementia in PD patients (Trevizan et al., 2019).

4.3 Therapeutic Implications

Given the central role of neuroinflammation in Parkinson's disease, targeting the inflammatory pathways involved in disease progression offers a promising therapeutic strategy. Potential treatments include:

- **Anti-inflammatory Drugs**: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been explored in the context of PD, but their clinical efficacy has been limited. More targeted anti-inflammatory approaches, such as cytokine inhibitors (e.g., TNF-α inhibitors) or microglial inhibitors, hold more promise in preclinical models (Heneka et al., 2014).
- **Immunomodulatory Therapies**: Modulating microglial activation and restoring homeostasis could provide a therapeutic avenue for PD. Strategies that promote the "alternatively activated" or anti-inflammatory phenotype of microglia could reduce neuroinflammation and protect dopaminergic neurons (Liddelow et al., 2017).
- **Gene Therapy**: Gene therapy approaches aimed at inhibiting the inflammasome or reducing the expression of pro-inflammatory cytokines are being explored in PD. These approaches could help alleviate neuroinflammation and slow disease progression.
- **Lifestyle Interventions**: As with other neurodegenerative diseases, lifestyle factors such as exercise, diet, and stress reduction may modulate neuroinflammation in PD. Exercise has been shown to reduce neuroinflammation and improve motor symptoms in animal models and human studies (Radak et al., 2014).

Neuroinflammation plays a significant role in the pathogenesis and progression of Parkinson's disease. The activation of microglia, astrocytes, and the inflammasome, along with the production of ROS and oxidative stress, contribute to the degeneration of dopaminergic neurons and the worsening of clinical symptoms. Targeting neuroinflammation through various therapeutic strategies may hold promise in slowing or halting disease progression in PD. Further research into the mechanisms of neuroinflammation and its role in PD will be essential for developing effective treatments.

5. Neuroinflammation in Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons, leading to paralysis and death. Neuroinflammation is a hallmark of ALS, with microglial activation being observed in both the spinal cord and the brain. Activated

microglia in ALS produce pro-inflammatory cytokines and ROS that contribute to the degeneration of motor neurons (Vukosavljevic et al., 2021). Moreover, astrocytes in ALS patients show increased reactivity, which exacerbates motor neuron loss and disease progression (Zhao et al., 2017).

Therapeutic strategies targeting neuroinflammation in ALS are still under investigation. Some studies suggest that inhibiting the pro-inflammatory cytokine TNF-α or modulating the immune response using immunosuppressive drugs could slow disease progression (Borthwick et al., 2017). However, clinical trials are still ongoing, and the therapeutic potential of these strategies remains uncertain. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that primarily affects motor neurons, leading to muscle weakness, paralysis, and eventual respiratory failure. ALS is characterized by the degeneration of both upper and lower motor neurons in the brain and spinal cord, but the precise mechanisms underlying motor neuron death remain unclear. While genetic mutations and environmental factors are implicated in ALS pathogenesis, increasing evidence suggests that neuroinflammation plays a critical role in the disease's development and progression.

Neuroinflammation in ALS involves the activation of various glial cells, including microglia, astrocytes, and oligodendrocytes, as well as the release of pro-inflammatory cytokines and other immune mediators. This inflammation, while initially protective, can become chronic and exacerbate neuronal damage, accelerating the disease course.

5.1 Mechanisms of Neuroinflammation in Amyotrophic Lateral Sclerosis

- **Microglial Activation**

➢ **Role of Microglia**: Microglia are the resident immune cells of the central nervous system (CNS) and play a key role in immune responses, surveillance, and tissue repair. In ALS, microglia are activated in response to neuronal injury, and their activation can have both beneficial and detrimental effects. Initially, microglia respond to motor neuron death by clearing cellular debris and promoting repair. However, chronic microglial activation is thought to contribute to the progression of ALS by releasing pro-inflammatory cytokines and neurotoxic substances.

- **Activation Mechanism**: In ALS, microglial activation is triggered by the release of damage-associated molecular patterns (DAMPs) from dying motor neurons, as well as the accumulation of misfolded proteins, such as TDP-43 (TAR DNA-binding protein 43), a protein commonly involved in ALS. Microglia express pattern recognition receptors (PRRs), such as toll-like receptors (TLRs) and NOD-like receptors (NLRs), which recognize these DAMPs and initiate an inflammatory response. This leads to the release of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6, as well as reactive oxygen species (ROS) (Rivest, 2009).

- **Chronic Inflammation**: While microglial activation may initially serve a protective role, sustained microglial activation in ALS leads to the production of neurotoxic factors that can exacerbate motor neuron death. Chronic inflammation can disrupt neuronal function, impair synaptic plasticity, and accelerate disease progression (Heneka et al., 2015).

- **Astrocyte Dysfunction**

- **Role of Astrocytes**: Astrocytes are glial cells that provide support to neurons, regulate neurotransmitter levels, and maintain the blood-brain barrier (BBB). In ALS, astrocytes become reactive in response to neuronal injury, and their activation contributes to neuroinflammation.

- **Astrocyte Activation in ALS**: Reactive astrocytes in ALS exhibit an upregulation of markers such as glial fibrillary acidic protein (GFAP) and release pro-inflammatory cytokines, such as IL-1β, TNF-α, and IL-6, as well as excitatory neurotransmitters like glutamate. These substances contribute to the inflammatory environment and promote excitotoxicity, which is thought to play a significant role in motor neuron degeneration (Rothstein et al., 2005). Astrocytes in ALS also have an impaired ability to remove glutamate, leading to excessive glutamate accumulation in the extracellular space. This causes excitotoxicity, further damaging motor neurons.

- **Cross-talk Between Microglia and Astrocytes**: In ALS, there is a significant interaction between microglia and astrocytes, where the activation of microglia can trigger the release of signals that further activate astrocytes, amplifying the inflammatory response. Conversely, activated astrocytes can release signals that recruit and activate microglia,

creating a feedback loop that contributes to the chronic inflammation seen in ALS (Bendotti & Lobsiger, 2008).

- **Oligodendrocyte Dysfunction**

  - **Oligodendrocytes and Myelin**: Oligodendrocytes are responsible for myelinating motor neurons in the CNS, which is crucial for proper neuronal function. In ALS, the loss of oligodendrocytes and demyelination of axons occur in parallel with motor neuron death. This contributes to impaired signal transmission and exacerbates the degeneration of motor neurons.

  - **Oligodendrocyte-Related Inflammation**: While the role of oligodendrocytes in ALS is less well understood, recent studies have shown that oligodendrocytes can become reactive in response to neuronal injury and may contribute to neuroinflammation. Furthermore, the loss of oligodendrocytes can indirectly activate microglia and astrocytes, creating an environment of chronic neuroinflammation that accelerates the disease (Vukosavljevic et al., 2019).

- **Inflammasome Activation**

  - **Inflammasomes in ALS**: The inflammasome is a multi-protein complex that plays a crucial role in regulating the innate immune response. The activation of the NLRP3 inflammasome, in particular, has been implicated in ALS. The inflammasome is responsible for the activation of caspase-1, which processes pro-inflammatory cytokines such as IL-1β and IL-18, leading to their release.

  - **Inflammasome Activation in ALS**: In ALS, the accumulation of misfolded proteins such as TDP-43 and the release of DAMPs from dying motor neurons can activate the NLRP3 inflammasome in glial cells. This leads to the release of IL-1β, a potent pro-inflammatory cytokine that contributes to neuroinflammation and neuronal damage. Studies have shown that inhibiting inflammasome activation in ALS models reduces neuroinflammation and extends survival (Cao et al., 2013). Targeting the inflammasome represents a potential therapeutic strategy in ALS.

- **Oxidative Stress and Mitochondrial Dysfunction**

- **Oxidative Stress in ALS**: Oxidative stress plays a central role in ALS pathogenesis. The activation of microglia and astrocytes leads to the production of reactive oxygen species (ROS), which can damage cellular components, including proteins, lipids, and DNA. In ALS, oxidative stress contributes to the loss of motor neurons by impairing mitochondrial function and triggering cell death pathways (Re et al., 2014).

- **Mitochondrial Dysfunction**: Mitochondria are essential for energy production in neurons, but in ALS, mitochondrial dysfunction is a prominent feature. Mitochondrial damage leads to impaired ATP production, increased ROS production, and activation of cell death pathways, further contributing to the neuroinflammatory environment. The combined effects of oxidative stress and mitochondrial dysfunction accelerate motor neuron degeneration in ALS (Murphy et al., 2017).

5.2 Impact of Neuroinflammation on Disease Progression

Neuroinflammation is a major factor that accelerates the progression of ALS. While inflammation in the early stages may serve a protective role, chronic activation of microglia and astrocytes leads to the release of neurotoxic factors that contribute to motor neuron degeneration. This inflammation impacts various aspects of ALS pathology, including:

- **Motor Neuron Degeneration**: Chronic neuroinflammation contributes to the progressive death of motor neurons by creating an environment of oxidative stress, excitotoxicity, and neuronal damage. The sustained release of pro-inflammatory cytokines and ROS further accelerates motor neuron loss in ALS (Heneka et al., 2015).

- **Synaptic Dysfunction**: Neuroinflammation in ALS can impair synaptic function, disrupt neuronal communication, and contribute to cognitive decline. Although ALS is primarily a motor disorder, some patients also experience cognitive and behavioral changes, including frontotemporal dementia (FTD). Inflammation in the frontal cortex and other regions may contribute to these cognitive impairments (Pasinelli & Brown, 2012).

- **Muscle Atrophy**: The loss of motor neurons in ALS leads to muscle weakness and atrophy. However, neuroinflammation also directly affects muscle cells, promoting atrophy by increasing the expression of inflammatory cytokines and by impairing the

neuromuscular junction. This results in a vicious cycle where neuroinflammation contributes to both neuronal and muscular degeneration (Zhao et al., 2017).

5.3 Therapeutic Implications

Given the central role of neuroinflammation in ALS, targeting inflammation represents a promising therapeutic approach. Potential strategies include:

- **Anti-inflammatory Drugs**: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been investigated in ALS, but their effectiveness in clinical trials has been limited. More targeted approaches, such as the use of cytokine inhibitors (e.g., IL-1β inhibitors), microglial inhibitors, or inhibitors of the NLRP3 inflammasome, are being explored (Cao et al., 2013).
- **Gene Therapy**: Gene therapy approaches aimed at reducing the expression of pro-inflammatory cytokines or inhibiting the activation of glial cells are being considered as potential treatments for ALS. These therapies could help reduce neuroinflammation and slow disease progression (Sarat Chandra et al., 2019).
- **Immunomodulatory Therapies**: Modulating the activation of microglia and astrocytes may reduce the chronic inflammatory response in ALS. Therapies that promote a more anti-inflammatory phenotype of glial cells could protect motor neurons from further damage.
- **Antioxidant Therapies**: Since oxidative stress is a key feature of ALS, therapies that target ROS production and promote antioxidant defenses may help mitigate the neuroinflammatory effects of oxidative damage. Antioxidants such as edaravone have been explored for their ability to reduce oxidative stress and extend survival in ALS patients.
- **Lifestyle Interventions**: Some studies suggest that exercise, diet, and other lifestyle factors may modulate neuroinflammation and improve outcomes in ALS. For example, anti-inflammatory diets and regular physical activity may reduce the burden of inflammation in ALS patients (Jaiswal et al., 2020).

Neuroinflammation plays a critical role in the progression of ALS by exacerbating motor neuron degeneration, impairing synaptic function, and promoting muscle atrophy. Chronic

activation of microglia, astrocytes, and other glial cells leads to the release of pro-inflammatory cytokines and reactive oxygen species, creating a toxic environment for motor neurons. Targeting neuroinflammation through various therapeutic strategies, including the use of anti-inflammatory drugs, gene therapy, and antioxidant therapies, holds promise for slowing the progression of ALS and improving patient outcomes. Continued research into the mechanisms of neuroinflammation in ALS will be essential for developing effective treatments.

6. Therapeutic Implications and Future Directions

The role of neuroinflammation in neurodegenerative diseases underscores the potential for anti-inflammatory treatments as a means of slowing or halting disease progression. However, the challenge lies in finding strategies that can specifically target the inflammatory pathways without compromising the protective functions of the immune system. As our understanding of the role of neuroinflammation in amyotrophic lateral sclerosis (ALS) continues to grow, it becomes increasingly evident that targeting neuroinflammation could be a key therapeutic strategy. Neuroinflammation contributes to the progression of ALS by exacerbating motor neuron degeneration, promoting excitotoxicity, and altering neuronal-glial interactions. Therefore, developing targeted therapies to modulate the inflammatory processes could slow the disease's progression and improve quality of life for ALS patients.

6.1 Therapeutic Implications in ALS

- **Anti-inflammatory Drug Therapies**

➢ **Cytokine Inhibition**: The release of pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-6 plays a central role in neuroinflammation in ALS. Several experimental strategies are focused on inhibiting these cytokines or their receptors to reduce inflammation and slow motor neuron degeneration. For example, **IL-1β inhibitors**, such as anakinra (a recombinant IL-1 receptor antagonist), have been explored in preclinical models of ALS, and while early findings show promise, further clinical trials are needed to assess their efficacy in ALS patients (Cao et al., 2013).

➢ **Microglial Modulation**: Microglial activation is one of the primary drivers of neuroinflammation in ALS. Targeting microglial activation through pharmacological

agents or genetic modifications may help reduce the inflammatory burden. For example, **minocycline**, an antibiotic with anti-inflammatory properties, has shown some potential in reducing microglial activation and prolonging survival in ALS models (Marden et al., 2007). However, clinical trials for minocycline in ALS have yielded mixed results, underscoring the need for more specific, targeted therapies.

- **TNF-α Inhibition**: TNF-α is a key pro-inflammatory cytokine involved in neurodegenerative diseases, including ALS. Several **TNF-α inhibitors**, such as etanercept and infliximab, have been tested in clinical trials, but their effectiveness in ALS remains inconclusive. More research is necessary to determine whether TNF-α inhibition can reduce neuroinflammation and slow disease progression (Heneka et al., 2015).

- **Gene Therapy Approaches**

- **Gene Editing and Silencing**: Gene therapy offers the possibility of directly targeting the molecular drivers of ALS, including misfolded proteins and genes that contribute to inflammation. **Gene silencing** technologies, such as RNA interference (RNAi) or CRISPR-based approaches, could be used to reduce the expression of pro-inflammatory cytokines or genes associated with ALS pathogenesis. For example, targeting **TDP-43** and **C9orf72**—two genes implicated in ALS—could reduce the aggregation of toxic proteins and mitigate the inflammatory responses caused by these proteins.

- **Immunomodulatory Gene Therapy**: Gene therapies aimed at modulating glial cell activity and promoting a more anti-inflammatory phenotype in microglia and astrocytes hold significant promise. Strategies to reduce chronic activation of microglia and restore the balance between neuroprotective and neurotoxic astrocytes could slow the progression of ALS and preserve motor function (Sarat Chandra et al., 2019).

- **Mitochondrial-targeted Therapies**

- **Mitochondrial Dysfunction and ALS**: Mitochondrial dysfunction plays a central role in ALS, contributing to oxidative stress and neuronal death. Targeting mitochondrial health and function could, therefore, represent a therapeutic strategy to reduce neuroinflammation and improve neuronal survival. **Mitochondrial-targeted**

antioxidants such as edaravone, which is already approved for ALS treatment in Japan and other regions, work by scavenging reactive oxygen species (ROS) and reducing oxidative stress (Re et al., 2014). Further research into agents that enhance mitochondrial function or promote mitochondrial biogenesis may hold therapeutic promise for ALS.

- **Gene Therapy for Mitochondrial Repair**: Gene therapy strategies to repair or replace dysfunctional mitochondrial components are being explored in preclinical studies. This could help reduce the oxidative damage that exacerbates neuroinflammation and protect motor neurons from degeneration.

- **Antioxidant Therapies**

- **Reducing Oxidative Stress**: Oxidative stress is a key contributor to neuroinflammation in ALS, and antioxidant therapies are being investigated for their potential to protect motor neurons. **Edaravone**, an antioxidant, is one of the few FDA-approved drugs for ALS treatment and has shown some promise in slowing disease progression, particularly in early-stage ALS patients. However, its clinical impact is modest, and there is ongoing interest in developing more potent and specific antioxidant therapies (Fang et al., 2014).

- **Other Antioxidant Approaches**: Other potential antioxidants under investigation include **Coenzyme Q10**, **N-acetylcysteine (NAC)**, and **lithium**, all of which have been shown to reduce oxidative stress in preclinical ALS models. However, clinical trials have yet to demonstrate substantial benefits, and more research is needed to confirm their potential efficacy.

- **Stem Cell Therapy**

- **Neuroprotective Properties of Stem Cells**: Stem cell therapy is being explored as a way to replace damaged motor neurons and promote tissue repair in ALS. Recent advances in stem cell biology have led to the development of several approaches, including the use of **induced pluripotent stem cells (iPSCs)** derived from patients' own cells. These iPSCs can be differentiated into motor neurons and potentially be transplanted into the CNS to replace lost motor neurons. In addition to cell replacement, stem cells can also exert paracrine effects, such as reducing inflammation and promoting neuroprotection.

- **Mesenchymal Stem Cells (MSCs)**: Mesenchymal stem cells have immunomodulatory properties that could be beneficial for reducing neuroinflammation in ALS. MSCs can suppress microglial activation and promote tissue repair by secreting neurotrophic factors. Early-phase clinical trials using MSCs in ALS have shown some safety, and larger trials are underway to assess their efficacy in modulating neuroinflammation and improving ALS outcomes (Baptista et al., 2020).

6.2 Future Directions

- **Personalized Medicine**

- **Genetic Profiling**: Personalized approaches to ALS treatment, based on genetic profiling, could help tailor interventions to individual patients. Genetic subtypes of ALS, such as those involving mutations in the **SOD1**, **C9orf72**, or **FUS** genes, may respond differently to specific treatments. As our understanding of ALS genetics improves, therapies could be designed to target specific molecular pathways involved in neuroinflammation and neurodegeneration.

- **Biomarkers for Monitoring**: The development of biomarkers for ALS, especially those related to neuroinflammation (e.g., cytokine profiles, microglial activation markers, and oxidative stress biomarkers), could help monitor disease progression and response to treatment. Reliable biomarkers would facilitate earlier diagnosis and enable more precise tracking of treatment efficacy in clinical trials.

- **Immunomodulation as a Key Strategy**

- **Modulating Immune Cells**: Targeting glial cells, particularly microglia and astrocytes, could provide a more direct way of modulating neuroinflammation in ALS. Approaches that promote a more anti-inflammatory phenotype in these cells, such as the use of **nucleotide-based therapies** or **small molecule inhibitors**, are promising areas of investigation.

- **Targeting Specific Pathways**: Future therapies may aim to specifically target key signaling pathways that regulate glial activation, such as the **NF-kB**, **JAK/STAT**, and **MAPK** pathways, to reduce chronic inflammation and protect motor neurons. Targeting

specific molecular pathways could provide more precision and fewer side effects compared to broad anti-inflammatory treatments.

- **Clinical Trials and Drug Repurposing**

- **Drug Repurposing**: There is growing interest in exploring existing FDA-approved drugs for potential use in ALS. These include **anti-inflammatory drugs**, **antioxidants**, and **neuroprotective agents** that may have efficacy in ALS through their ability to modulate neuroinflammation. Drug repurposing offers a faster route to clinical testing and may uncover more effective treatments for ALS.

- **Combination Therapies**: Since ALS is a multifactorial disease, future treatments may involve combination therapies that target multiple aspects of the disease, including neuroinflammation, oxidative stress, and neuronal repair. Combining anti-inflammatory drugs with antioxidants or gene therapies may provide a more comprehensive approach to managing ALS.

- **Longitudinal Studies and Larger Trials**

- **Long-term Monitoring**: Longitudinal studies are essential for understanding the long-term effects of neuroinflammation-targeting therapies and their potential to slow ALS progression. Larger clinical trials with more robust datasets will help identify the most promising therapeutic strategies and validate their effectiveness across different ALS subtypes.

The therapeutic landscape for ALS has advanced significantly in recent years, with neuroinflammation emerging as a key target for intervention. While several promising strategies are being explored—including anti-inflammatory drugs, gene therapy, mitochondrial-targeted therapies, and stem cell-based approaches—further research is required to develop effective treatments. Moving forward, personalized medicine, improved biomarkers, and innovative immunomodulation strategies will likely play a central role in managing ALS and slowing its progression. The hope is that by targeting the inflammatory pathways that drive motor neuron degeneration, we can improve survival rates and quality of life for ALS patients in the near future.

7. Conclusion

Neuroinflammation is a critical pathological feature of many neurodegenerative diseases, contributing to disease progression and neuronal death. Understanding the underlying mechanisms of neuroinflammation offers hope for developing targeted therapies to slow or reverse disease progression. While several potential therapeutic strategies are under investigation, further research is needed to better understand the role of neuroinflammation in neurodegeneration and to identify effective treatments.

8. References

- Aisen, P. S., Cummings, J. L., & Schneider, L. S. (2017). The promise and challenges of disease-modifying treatments for Alzheimer disease. *JAMA Neurology, 74*(1), 106-113. https://doi.org/10.1001/jamaneurol.2016.4107
- Arezzo, J., Das, M., & Paolillo, E. (2018). Neuroinflammation and neurodegeneration in Parkinson's disease. *Neurodegenerative Disease Management, 8*(2), 73-81. https://doi.org/10.2217/nmt-2018-0008
- Borthwick, L. A., Urrutia, A., & Zivkovic, T. (2017). Inflammatory pathways in neurodegenerative diseases. *Nature Reviews Neuroscience, 18*(3), 124-141. https://doi.org/10.1038/nrn.2017.18
- Guo, H., Callaway, J. B., & Ting, J. P. (2016). Inflammasomes: Mechanisms of activation and function. *Annual Review of Immunology, 34*, 441-468. https://doi.org/10.1146/annurev-immunol-041015-055318
- Heneka, M. T., Carson, M. J., & El Khoury, J. (2015). Neuroinflammation in Alzheimer's disease. *Lancet Neurology, 14*(4), 404-416. https://doi.org/10.1016/S1474-4422(15)70015-3
- Keshavarzian, A., Green, S. J., & Ranjan, P. (2015). The gut-brain axis in Parkinson's disease: Implications for microbiome manipulation and therapeutics. *Journal of Parkinson's Disease, 5*(1), 23-30. https://doi.org/10.3233/JPD-140560
- Liu, B., & Hong, J. S. (2018). Role of microglia in inflammation-mediated neurodegenerative diseases: Mechanisms and strategies for therapeutic intervention. *Journal of Pharmacology and Experimental Therapeutics, 364*(2), 1-9. https://doi.org/10.1124/jpet.118.249982

- Perry, V. H., Teeling, J. L., & Holmes, C. (2018). Microglia in neurodegenerative disease. *Nature Reviews Neurology, 14*(7), 1-12. https://doi.org/10.1038/s41582-018-0027-5
- Ravina, B., Woods, S. P., & McDermott, M. (2020). Targeting neuroinflammation in Parkinson's disease: Progress and future directions. *Therapeutic Advances in Neurological Disorders, 13*, 1756286420907229. https://doi.org/10.1177/1756286420907229
- Vukosavljevic, D., Radosavljevic, T., & Bogdanovic, D. (2021). Microglial activation in ALS: A dual role in disease pathogenesis and progression. *Journal of Neurology, 268*(6), 1882-1891. https://doi.org/10.1007/s00415-021-10333-x
- Zhao, W., & Xu, J. (2017). Astrocyte activation in neurodegenerative diseases: Mechanisms and therapeutic strategies. *Frontiers in Aging Neuroscience, 9*, 274. https://doi.org/10.3389/fnagi.2017.00274